BRAF and colorectal carcinoma: This is in keeping with an earlier study by Di Nicolantonio and colleagues [214], where the response to panitumumab or cetuximab was found to be impeded by the presence of BRAF V600E mutation and restored (in a cellular model of CRC cells) by BRAF inhibitor sorafenib [214].